Efficacy and safety of levetiracetam in clinical practice: Results of the SKATE™ trial from Belgium and The Netherlands

Seizure

Volumn 15, Issue 6, 2006, Pages 434-442

  Lambrechts, D A J E ^a   Sadzot, B ^b   van Paesschen, W ^c   van Leusden, J A ^d   Carpay, J ^e   Bourgeois, P ^f   Urbain, E ^g   Boon, P A J M ^a,h  

^a EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Location Alkmaar   (Netherlands)

^e Gooi Noord Hospital   (Netherlands)

^f Heilig Hart Roeselare   (Belgium)

^g Centre Hospitalier Notre Dame et Reine Fabiola   (Belgium)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Add on treatment; Clinical practice; Levetiracetam; Partial onset seizures; Refractory epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; ASTHENIA; BELGIUM; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; NETHERLANDS; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; PATIENT SELECTION; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK REDUCTION; SOMNOLENCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; BELGIUM; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PIRACETAM; PROSPECTIVE STUDIES;

EID: 33746925289     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2006.05.013     Document Type: Article

References (28)

1. World Health Organization. Epilepsy: aetiology, epidemiology and prognosis. WHO Fact Sheet No. 165. Revised February 2001.
2. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on clinical investigation of medicinal products in the treatment of epileptic disorders. CPMP/EWP/566/98 rev.1 (16 November 2000).
3. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. New England Journal of Medicine 342 (2000) 314-319
4. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?. Epilepsia 42 Suppl. 4 (2001) 13-18
5. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America 101 (2004) 9861-9866
6. 2+ current in pyramidal neurones of rat hippocampal slices. Neuroscience Letters 306 (2001) 5-8
7. Lukyanetz E.A., Shrkryl V.M., and Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43 1 (2002) 9-18
8. 2+ transients and epileptiform potentials in hippocampal neurons. Neuropharmacology and Neurotoxicology 14 3 (2003) 471-475
9. Rigo J.-M., Hans G., Nguyen L., Rocher V., Belachew S., Malgrange B., et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. British Journal of Pharmacology 136 (2002) 659-672
10. Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacology and Therapeutics 85 (2000) 77-85
11. Perucca E., Gidal B.E., and Baltès E. Effect of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Research 53 (2003) 47-56
12. -1 in adult patients with refractory epilepsy. Seizure 12 (2003) 141-149
13. Shorvon S.D., Löwenthal A., Janz D., Bielen E., Loiseau P., and for the European Levetiracetam Study Group. Multicenter, double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41 (2000) 1179-1186
14. Boon P., Chauvel P., Pohlmann-Eden B., Otoul C., and Wroe S. Dose response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Research 48 (2002) 77-89
15. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., Leppik I., and The United States Levetiracetam Study Group. Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
16. Ben-Menachem E., Falter U., and for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/day in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41 10 (2000) 1276-1283
17. Privitera M. Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia 42 Suppl. 4 (2001) 31-35
18. Privitera M.D., Edrich P., and Godfroid P. Dose-response relationship of levetiracetam. European Journal of Neurology 9 Suppl. 2 (2002) 177-178 Abstract P3060
19. French J., and Arrigo C. Fast action of levetiracetam. Epilepsia 44 Suppl. 9. (2003) Abstract and Poster 2.262
20. Shorvon S.D., and van Rijckevorsel K. A new antiepileptic drug. Levetiracetam, a pyrrolidone recently licensed as an antiepileptic drug. Journal of Neurology, Neurosurgery and Psychiatry 72 (2002) 426-429 [Corrigendum: Journal of Neurology, Neurosurgery and Psychiatry 2002; 73: 102]
21. Ben-Menachem E., Edrich P., Van Vleymen B., Sander J.W.A.S., and Schmidt B. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Research 53 (2003) 57-64
22. Morrell M.J., Leppik I., French J., Ferrendelli J., Han J., and Magnus L. The KEEPER™ trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Research 54 (2003) 153-161 [Corrigendum: Epilepsy Research 2003; 56: 209-210]
23. ®) as adjunctive therapy in patients with refractory epilepsy. Epilepsia 44 Suppl. 8 (2003) 153 Abstract and Poster P463
24. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22 (1981) 489-501
25. ® Summary of Product Characteristics. 2003.
26. Harden C. Safety profile of levetiracetam. Epilepsia 42 Suppl. 4 (2001) 36-39
27. French J., Edrich P., and Cramer J.A. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Research 47 (2001) 77-90
28. Cramer J.A., De Rue K., Devinsky O., Edrich P., and Trimble M.R. A systematic review of the behavioral effects of levetiracetam in adults wit epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behavior 4 (2003) 124-132